Thomas M. Cardillo

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

David M. Goldenberg, Thomas M. Cardillo, Serengulam V. Govindan et al. · Oncotarget · 2015 · 447 citations · Full text

Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey et al. · Clinical Cancer Research · 2011 · 285 citations · Full text

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers

Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey et al. · Bioconjugate Chemistry · 2015 · 280 citations

Anti-trop-2/sn-38 Antibody–drug Conjugate, Immunology, Immunoediting +20

Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting

Edmund A. Rossi, David M. Goldenberg, Thomas M. Cardillo et al. · Proceedings of the National Academy of Sciences · 2006 · 210 citations · Full text

Engineering, Lock Method, Defined Composition +20

Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a Human Multiple Myeloma Xenograft and in Monkeys

Puja Sapra, Rhona Stein, J. Pickett et al. · Clinical Cancer Research · 2005 · 168 citations